about
Nitric oxide and cardiovascular effects: new insights in the role of nitric oxide for the management of osteoarthritisRenal artery stenosis-when to screen, what to stent?Influenza H1N1 (swine flu) vaccination: a safety surveillance feasibility study using self-reporting of serious adverse events and pregnancy outcomesPromoting public awareness of randomised clinical trials using the media: the 'Get Randomised' campaign.Acid-suppression medications and bacterial gastroenteritis: a population-based cohort study.Effectiveness of newspaper advertising for patient recruitment into a clinical trial.Managing security and privacy concerns over data storage in healthcare research.Protocol of the Febuxostat versus Allopurinol Streamlined Trial (FAST): a large prospective, randomised, open, blinded endpoint study comparing the cardiovascular safety of allopurinol and febuxostat in the management of symptomatic hyperuricaemia.Spironolactone use and risk of incident cancers: a retrospective, matched cohort study.Quantifying the real life risk profile of inhaled corticosteroids in COPD by record linkage analysisImpact of allopurinol use on urate concentration and cardiovascular outcomeDoes offering an incentive payment improve recruitment to clinical trials and increase the proportion of socially deprived and elderly participants?Monotherapy versus dual therapy for the initial treatment of hypertension (PATHWAY-1): a randomised double-blind controlled trialSpironolactone and risk of incident breast cancer in women older than 55 years: retrospective, matched cohort studyCluster randomized trials of prescription medicines or prescribing policy: public and general practitioner opinions in ScotlandSpironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): a randomised, double-blind, crossover trialEffect of amiloride, or amiloride plus hydrochlorothiazide, versus hydrochlorothiazide on glucose tolerance and blood pressure (PATHWAY-3): a parallel-group, double-blind randomised phase 4 trial.Cardiovascular safety of lumiracoxib: a meta-analysis of randomised controlled trials in patients with osteoarthritisPioglitazone and bladder cancer: a propensity score matched cohort studyMethodology of a large prospective, randomised, open, blinded endpoint streamlined safety study of celecoxib versus traditional non-steroidal anti-inflammatory drugs in patients with osteoarthritis or rheumatoid arthritis: protocol of the standard cMethods of a large prospective, randomised, open-label, blinded end-point study comparing morning versus evening dosing in hypertensive patients: the Treatment In Morning versus Evening (TIME) studyMolecular and clinical investigations in patients with low-renin hypertension.Multicentre, prospective, randomised, open-label, blinded end point trial of the efficacy of allopurinol therapy in improving cardiovascular outcomes in patients with ischaemic heart disease: protocol of the ALL-HEART study.Incidence and prevalence of multiple sclerosis in the UK 1990-2010: a descriptive study in the General Practice Research Database.Association between cardiovascular events and sodium-containing effervescent, dispersible, and soluble drugs: nested case-control study.Treatment of osteoarthritis in hypertensive patients.Antiplatelet drug interactions.Up-titration of allopurinol in patients with gout.Cardiovascular risk associated with sodium-containing medicines.Exaggerated Exercise Blood Pressure Response and Future Cardiovascular Disease.Comparison of the effects of antihypertensive agents on central blood pressure and arterial stiffness in isolated systolic hypertension.The effects of urotensin II and urantide on forearm blood flow and systemic haemodynamics in humans.Poster advertisements in practice waiting rooms to recruit patients to the Treatment In Morning vs. Evening (TIME) online study.Pulse-wave analysis: clinical evaluation of a noninvasive, widely applicable method for assessing endothelial function.Infliximab improves endothelial dysfunction in systemic vasculitis: a model of vascular inflammation.Aldehyde dehydrogenase 2 plays a role in the bioactivation of nitroglycerin in humans.The use of 18-fluoro-dihydroxyphenylalanine and 18-fluorodeoxyglucose positron emission tomography scanning in the assessment of metaiodobenzylguanidine-negative phaeochromocytoma.Combination Therapy Is Superior to Sequential Monotherapy for the Initial Treatment of Hypertension: A Double-Blind Randomized Controlled Trial.The Treatment In Morning versus Evening (TIME) study: analysis of recruitment, follow-up and retention rates post-recruitment.A novel drug management system in the Febuxostat versus Allopurinol Streamlined Trial: A description of a pharmacy system designed to supply medications directly to patients within a prospective multicenter randomised clinical trial.
P50
Q21195404-18559A0E-710C-433F-A2F5-B44E71EC4815Q26829330-79F02E06-43D3-4B86-B094-E250CDEF5817Q30409462-7F026268-907E-49E4-B402-F56013E983C3Q33633652-F6EEE2A9-4F34-4F11-8363-F6D2CEF772EBQ33666086-654984B4-07A0-414D-BB38-7BF0EBD8FA9AQ33888009-88BAA278-5803-44DF-9095-443EBC7EB62BQ33945632-BBAB2711-D5AE-4E6A-90DC-67D5F4AAD296Q33996337-D197E877-CF5A-4153-8C5B-50EA41A2FD0AQ34542518-30E66BDA-4CAB-43B4-9D37-D0CE04D8AB72Q34551086-EBA8B629-97F6-4E24-A773-A0C93DB8FA2BQ34830158-8080297C-10EF-4B05-87DE-272F6C7C435AQ35190321-F4A6F080-2ECA-444A-BC8F-6AF4C911DAB6Q35963836-C565B56B-F519-465F-808A-CB5D84495E9AQ36094069-40BD3C88-9584-46DF-A7D1-51465F3D2341Q36220238-ECC08089-B74A-4550-91F1-E74AB449E894Q36305422-ADD72018-B3ED-41F3-9348-713F10D11F81Q36506245-AF114C49-070B-4015-84BB-5ED6B965C65BQ36542583-8D1E4807-878C-463C-84E9-F86C0E887879Q36562522-1369AFAF-994B-4B77-BB63-6BAFB70098D4Q36584086-4EEB9109-3A0C-483D-98C9-4875B1B8B00CQ36602978-B17A9BC2-6E7D-479D-B01C-C8D733A553B0Q37243928-8FC0E57C-6ED1-48F7-B276-DCD268DAD9C6Q37251800-795F37CE-A759-48B5-AF8A-217D33C4B0AFQ37465626-20E48FD4-6C55-4C56-B0D0-58D54741B2A5Q37503738-C530ACD6-EFA0-46FB-AF3D-CBA7508EDFD6Q37670886-CEB9FBDC-DE44-4A0F-960E-12E9AE731B3BQ37809111-B10E42A1-9079-4059-AB34-1789ADFD420EQ38190246-9C478C9E-89C8-4E65-8487-69F7DF0B6B63Q38258617-4524BD2D-A0F1-425B-B7CB-E53A1B172D57Q38978393-1BB9E44A-689E-4A26-B184-A066716A3FA6Q39974632-CEA77A29-DBB5-40B5-B502-74E28AEB43EBQ42283626-DB501983-6A23-4F7D-B3FF-9FFD521D1737Q42656769-2144ED43-738F-4171-9AC7-8085750CD012Q43852832-02F40202-1009-4579-8CE2-8FE49C4F037AQ44810026-D7441206-AE15-45CE-B835-5B62BF932211Q46624700-A1D15081-32CF-49FD-B093-221038087344Q46983572-7A3D7856-2E3C-480B-BCAE-1F554CFF5597Q47124918-BE57BFDB-95E2-4F9A-BA85-58BAB492A954Q47132602-205534FF-F148-4DBB-B480-82C1B17E11DEQ47753935-A00CA554-C2CA-47A7-B103-EA6CBB95F5C7
P50
description
hulumtues
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Isla Mackenzie
@fr
Isla S Mackenzie
@es
Isla S Mackenzie
@nl
Isla S Mackenzie
@sl
Isla S. Mackenzie
@en
type
label
Isla Mackenzie
@fr
Isla S Mackenzie
@es
Isla S Mackenzie
@nl
Isla S Mackenzie
@sl
Isla S. Mackenzie
@en
prefLabel
Isla Mackenzie
@fr
Isla S Mackenzie
@es
Isla S Mackenzie
@nl
Isla S Mackenzie
@sl
Isla S. Mackenzie
@en
P106
P1153
56250129400
P21
P31
P496
0000-0002-3680-7127
P569
2000-01-01T00:00:00Z